Remote Assessment of Disease and Relapse in Central Nervous System Disorders


Start Date
End Date
IMI2 - Call 3
Grant agreement number

IMI Funding
11 000 000
EFPIA in kind
13 580 029
1 035 832
Total Cost25 615 861


The RADAR-CNS project aims to develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. The key goal of the project is to improve patients’ symptoms and quality of life and also to change how these and other chronic disorders are treated.

Epilepsy, depression, and multiple sclerosis are distinct disorders that affect 400 million people worldwide, with different causes and symptoms, all of which can be severely detrimental to patients’ quality of life and life expectancy. For all three disorders, patients often experience periods where their symptoms are manageable, followed by periods of deterioration and acute illness (relapse). Patient surveys have repeatedly highlighted the need to predict when relapses will happen and to improve the treatments which are available to stop them from occurring. Continuous remote assessment using smartphones and wearable devices provides a complete picture of a patient’s condition at a level of detail which was previously unachievable. Moreover, it could potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.

Achievements & News

RADAR-CNS recruits first participants in depressive disorder study
January 2018

IMI’s RADAR-CNS project has recruited the first participants in the depression component of its study. The aim of RADAR-CNS is to develop new ways of measuring major depressive disorder, epilepsy and multiple sclerosis (MS) using wearable devices and smartphone technology. ###The first depression study participants have now received FitBit Charge 2 devices as well as smartphone apps. The participants will wear the FitBit for up to 24 hours a day, allowing it to capture information on their heart rate, sleep quality, and physical activity levels. Every few weeks, they will answer a short series of questions via the RADAR-CNS apps. Faith Matcham, post-doctoral research associate at RADAR-CNS, hopes to recruit around fifty more people over the coming months. ‘We’re so excited to be starting recruitment – this study will provide important information about how useable the RADAR-CNS platform is, as well as providing us with data which might be invaluable for improving our understanding of the course of major depression,’ she said. The epilepsy component of the study got underway in June last year, and the project team hopes to start recruitment for the multiple sclerosis study soon.

Participants Show participants on map

EFPIA companies
  • Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom
  • H. Lundbeck A/S, Valby, Denmark
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • MSD IT Global Innovation Center s.r.o., Prague, Czech Republic
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Centro De Investigacion Biomedica En Red, Madrid, Spain
  • Charité – Universitätsmedizin Berlin, Berlin, Germany
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • King's College London, London, United Kingdom
  • Northwestern University, Evanston, Illinois, United States
  • Provincia Lombardo-Veneta - Ordine Ospedaliero di San Giovanni di Dio— Fatebenefratelli, Brescia, Italy
  • Region Hovedstaden, Hilleroed, Denmark
  • STICHTING VUmc, Amsterdam, Netherlands
  • Stichting imec Nederland, Eindhoven, Netherlands
  • Universitaetsklinikum Freiburg, Freiburg, Germany
  • University of Nottingham, Nottingham, United Kingdom
  • Università Vita-Salute San Raffaele, Milano, Italy
  • Università degli Studi di Bergamo, Bergamo, Italy
  • Universität Passau, Passau, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Stichting Lygature, Utrecht, Netherlands
Third parties
  • Fundació Sant Joan de Deu, Esplugues de Llobregat, Spain
  • Ospedale San Raffaele, Milano, Italy
  • The Hyve B.V., Utrecht, Netherlands
Non EFPIA companies
  • Intel Corporation (UK) Ltd, Swindon, United Kingdom
  • Software AG, Darmstadt, Germany


Project coordinator
Matthew Hotopf
King's College London
Project leadership
Vaibhav A. Narayan
Janssen Research & Development